Page 965 - Clinical Immunology_ Principles and Practice ( PDFDrive )

932 Part Seven Organ-Specific Inflammatory Disease

On tHe HOrIZOn
• The advent of new genetic and molecular techniques and new disease
models has led to exciting progress in our understanding of the biology
of the glomerulus, the pathogenesis of many glomerular diseases,
and the influence of genetic variants on disease predisposition and
progression.
• It is anticipated that these insights should lead to better noninvasive
diagnostic techniques, biomarkers, and predictors of prognosis and
relapse and facilitate a more personalized approach to therapy rather
than a one-size-fits-all approach.
• Novel targeted therapies are on the horizon that will interrupt or
modulate the underlying pathophysiology of the individual diseases
and also halt the downstream pathways of injury and fibrosis common
to all of the glomerular diseases.

FIG 68.16 Scleroderma Renal Crisis. Renal arteriole demon-
strates extensive fibrin deposition (dark material) within multiple Please check your eBook at https://expertconsult.inkling.com/
layers of its wall. The lumen is further compromised by severe for self-assessment questions. See inside cover for registration
swelling and intimal hyperplasia (Masson trichrome stain). details.

REFERENCES

1. Couser WG, Johnson RJ. The etiology of glomerulonephritis: roles of
infection and autoimmunity. Kidney Int 2014;86:905–14.
increased the 1-year survival of patients with SCR. Prompt 2. Mastroianni-Kirsztajn G, Hornig N, Schlumberger W. Autoantibodies in
treatment with ACEIs is recommended for hypertensive and renal diseases - clinical significance and recent developments in
normotensive SRC because these agents may reverse the process serological detection. Front Immunol 2015;6:221.
by interfering with angiotensin II–mediated vasoconstriction 3. Floege J, Amann K. Primary glomerulonephritides. Lancet
2016;387:2036–48.
and by inhibiting the degradation of the potent vasodilator 4. Waldman M, Crew RJ, Valeri A, et al. Adult minimal-change disease:
bradykinin by ACE. Despite this impressive impact of ACEIs clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol
on clinical outcomes, approximately one-third to one-half of 2007;2:445–53.
patients still progress to early death or renal failure. This has 5. Maas RJ, Deegens JK, Wetzels JF. Permeability factors in idiopathic
prompted continued investigation of additional treatment strate- nephrotic syndrome: historical perspectives and lessons for the future.
gies, including blockade of the RAA system at multiple sites Nephrol Dial Transplant 2014;29:2207–16.
(using, for example, a direct renin inhibitor) as well as addition 6. Fornoni A, Sageshima J, Wei C, et al. Rituximab targets podocytes in
of potent vasodilators (e.g., prostacyclin or an endothelin receptor recurrent focal segmental glomerulosclerosis. Sci Transl Med
antagonist). 2011;3:85ra46.
7. Yu CC, Fornoni A, Weins A, et al. Abatacept in B7-1-positive proteinuric
Renal Disease of Sjögren Syndrome kidney disease. New Engl J Med 2013;369:2416–23.
8. D’Agati VD, Alster JM, Jennette JC, et al. Association of histologic
A variety of renal manifestations occur in approximately one-third variants in FSGS clinical trial with presenting features and outcomes. Clin
of patients with primary Sjögren syndrome (Chapter 54), includ- J Am Soc Nephrol 2013;8:399–406.
ing tubular dysfunction (proximal or, more often, distal tubular 9. Fernandez-Fresnedo G, Segarra A, Gonzalez E, et al. Rituximab treatment
acidosis, Fanconi syndrome, hypokalemia that may be profound of adult patients with steroid-resistant focal segmental glomerulosclerosis.
and associated with paralysis, Bartter syndrome, Gitelman Clin J Am Soc Nephrol 2009;4:1317–23.
syndrome, nephrogenic diabetes insipidus), as well as renal calculi, 10. Iijima K, Sako M, Nozu K, et al. Rituximab for childhood-onset,
nephrocalcinosis, interstitial nephritis, pseudolymphoma, nec- complicated, frequently relapsing nephrotic syndrome or
48
rotizing vasculitis, and glomerulopathy. Studies of renal steroid-dependent nephrotic syndrome: a multicentre, double-blind,
randomised, placebo-controlled trial. Lancet 2014;384:1273–81.
pathology among patients with primary Sjögren syndrome have 11. Malaga-Dieguez L, Bouhassira D, Gipson D, et al. Novel therapies for
shown that acute and/or chronic tubulointerstitial nephritis is FSGS: preclinical and clinical studies. Adv Chronic Kidney Dis
the predominant lesion. A diverse range of glomerular diseases, 2015;22:e1–6.
including MN and proliferative glomerulonephritis (focal or 12. Coppo R. Different targets for treating focal segmental glomerular
diffuse, and membranoproliferative), have been reported in sclerosis. Contrib Nephrol 2013;181:84–90.
primary Sjögren syndrome. In such cases, the possibility of overlap 13. Beck LH Jr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2
with SLE should be considered. Immunosuppressive therapy for receptor as target antigen in idiopathic membranous nephropathy. N
renal manifestations of primary Sjögren syndrome should be Engl J Med 2009;361:11–21.
individualized on the basis of activity and severity of the glo- 14. Tomas NM, Beck LH Jr, Meyer-Schwesinger C, et al. Thrombospondin
merular and/or tubulointerstitial nephritis. Patients with serious type-1 domain-containing 7A in idiopathic membranous nephropathy.
New Engl J Med 2014;371:2277–87.
complications of tubular dysfunction may warrant immunosup- 15. Hoxha E, Thiele I, Zahner G, et al. Phospholipase A2 Receptor
pressive therapies based on preliminary evidence that autoantibod- Autoantibodies and Clinical Outcome in Patients with Primary
ies (against, for example, carbonic-anhydrase-II) as well as Membranous Nephropathy. J Am Soc Nephrol 2014;25:1357–66.
cell-mediated injury likely contribute to at least some of those 16. Waldman M, Austin HA 3rd. Treatment of idiopathic membranous
disorders. nephropathy. J Am Soc Nephrol 2012;23:1617–30.